Your browser doesn't support javascript.
loading
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
Kalin, Jay H; Bergman, Joel A.
Afiliación
  • Kalin JH; Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Illinois 60612, United States. jkalin1@jhmi.edu
J Med Chem ; 56(16): 6297-313, 2013 Aug 22.
Article en En | MEDLINE | ID: mdl-23627282
ABSTRACT
This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Histona Desacetilasas Límite: Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Histona Desacetilasas Límite: Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos